(12) **Translation of European patent specification**

(11) **NO/EP 2605652 B1**

NORWAY

(19) NO

(51) Int Cl.

A01N 35/00 (2006.01) ***C07D 405/06 (2006.01)***
A61K 31/12 (2006.01) ***C07D 405/10 (2006.01)***
A61P 25/00 (2006.01) ***C07D 407/10 (2006.01)***
C07C 49/784 (2006.01) ***C07D 409/06 (2006.01)***
C07D 213/50 (2006.01) ***C07D 409/10 (2006.01)***
C07D 319/18 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.04.09
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.11.08
(86)	European Application Nr.	11818727.7
(86)	European Filing Date	2011.08.17
(87)	The European Application's Publication Date	2013.06.26
(30)	Priority	2010.08.18, US, 374687 P 2010.12.29, US, 201061427974 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Samumed, LLC, 9381 Judicial Drive Suite 160, San Diego, California 92121, US-USA
(72)	Inventor	KC, Sunil, Kumar, 10504 Clasico Court, San Diego, California 92127, US-USA WALLACE, David, Mark, 6448 Peinado Way, San Diego, California 92121, US-USA HOOD, John, 10831 Vereda Sol del Dios, San Diego, California 92130, US-USA BARROGA, Charlene, F., 8950 Costa Verde, No.4237, San Diego, California 92122, US-USA
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54) Title **DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS**

(56) References Cited:

WO-A1-2010/075551, US-A- 4 014 889, US-A- 4 032 526, US-A1- 2005 267 110, YOSHIMURA HIROYUKI ET AL: "Discovery of Novel and Potent Retinoic Acid Receptor.alpha. Agonists: Syntheses and Evaluation of Benzofuranyl-pyrrole and Benzothiophenyl-pyrrole Derivatives", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 43, 1 January 2000 (2000-01-01), pages 2929-2937, XP002214937, ISSN: 0022-2623, DOI: 10.1021/JM000098S, US-A1- 2009 232 754, US-A1- 2010 152 493, US-B2- 7 041 837, F. V. BRUCHHAUSEN, K. LINGNER: "Eine Synthese von DL-Asarinin und DL-Sesamin", ARCHIV DER PHARMAZIE, vol. 290, 1957, pages 1-16, XP002718639,, US-A1- 2008 146 555

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav

1. Forbindelse eller farmasøytisk akseptabelt salt derav med strukturen i formel I:



I

hvor R^1 er et substituert eller usubstituert heteroaryl, hvor heteroarylet er valgt fra gruppen bestående av:



underlagt den betingelse at et karbonatom i R^1-heteroarylet er knyttet til karbonylet;

R^2 er et substituert eller usubstituert aryl, hvor arylet er valgt fra fenyl eller naftyl; og

R^3, R^4, R^5 og R^6 er H.

2. Forbindelse ifølge krav 1, hvor R^1 er



3. Forbindelse ifølge krav 1, hvor R^2 er et substituert eller usubstituert fenyl.

4. Forbindelse ifølge krav 1, hvor R^1 er


;

og R^2 er et substituert eller usubstituert fenyl.

5. Forbindelse ifølge krav 4, hvor forbindelsen med formel I er:


.

6. Forbindelse ifølge krav 4, hvor forbindelsen med formel I er:


.

7. Forbindelse ifølge krav 4, hvor forbindelsen med formel I er:


.

8. Forbindelse ifølge krav 1, med en struktur valgt fra gruppen bestående av:


,


,


,


,


,

,

,

,

og


.

9. Farmasøytisk sammensetning, omfattende en terapeutisk virksom mengde av en forbindelse ifølge krav 1 eller et farmasøytisk akseptabelt salt derav med strukturen i formel I:



I

hvor R^1 er et substituert eller usubstituert heteroaryl, hvor heteroarylet er valgt fra gruppen bestående av


,
,

og

 ;

underlagt den betingelse at et karbonatom i R^1-heteroarylet er knyttet til karbonylet;

R^2 er et substituert eller usubstituert aryl, hvor arylet er valgt fra fenyl eller naftyl; og

R^3, R^4, R^5 og R^6 er H;

og et farmasøytisk akseptabelt tilsetningsmiddel.

10. Farmasøytisk sammensetning ifølge krav 9, hvor R^1 er

 .

11. Farmasøytisk sammensetning ifølge krav 9, hvor R^2 er et substituert eller usubstituert fenyl.

12. Farmasøytisk sammensetning ifølge krav 9, hvor R^1 er

 ;

og R^2 er et substituert eller usubstituert fenyl.

13. Farmasøytisk sammensetning ifølge krav 9, med en struktur valgt fra gruppen bestående av:


,

,

,

,

,

,

,

,

og


,

eller et farmasøytisk akseptabelt salt derav.

14. Farmasøytisk sammensetning ifølge krav 9, hvor forbindelsen med formel I er:


,

eller et farmasøytisk akseptabelt salt derav.

15. Farmasøytisk sammensetning ifølge krav 9, hvor forbindelsen med formel I er:



,

eller et farmasøytisk akseptabelt salt derav.

16. Farmasøytisk sammensetning ifølge krav 9, hvor forbindelsen med formel I er:



,

eller et farmasøytisk akseptabelt salt derav.